While Y-Mabs Therapeutics Inc has underperformed by -11.62%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, YMAB fell by -71.60%, with highs and lows ranging from $17.78 to $3.86, whereas the simple moving average fell by -56.83% in the last 200 days.
On April 22, 2025, BofA Securities Downgraded Y-Mabs Therapeutics Inc (NASDAQ: YMAB) to Underperform. A report published by Oppenheimer on November 18, 2024, Initiated its previous ‘Outperform’ rating for YMAB. Cantor Fitzgerald also rated YMAB shares as ‘Overweight’, setting a target price of $20 on the company’s shares in an initiating report dated August 16, 2024. Truist Initiated an Buy rating on June 28, 2024, and assigned a price target of $21. Wedbush May 10, 2023d its ‘Neutral’ rating to ‘Outperform’ for YMAB, as published in its report on May 10, 2023. Morgan Stanley also rated the stock as ‘Underweight’.
Analysis of Y-Mabs Therapeutics Inc (YMAB)
Further, the quarter-over-quarter increase in sales is 13.41%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Y-Mabs Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -30.74% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.85, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and YMAB is recording an average volume of 406.29K. On a monthly basis, the volatility of the stock is set at 9.90%, whereas on a weekly basis, it is put at 12.31%, with a loss of -13.59% over the past seven days. Furthermore, long-term investors anticipate a median target price of $16.75, showing growth from the present price of $4.26, which can serve as yet another indication of whether YMAB is worth investing in or should be passed over.
How Do You Analyze Y-Mabs Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 23.82%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 60.15% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
YMAB shares are owned by institutional investors to the tune of 60.15% at present.
